Having originally been built on research into a cell therapy for cardiology, Celyad started back in 2007. Now Rawadi explained it’s coming to the end of a cycle for the Cardiology programme. So naturally, they asked what next?
Celyad is aso honing in on the problem of cell-therapies for solid tumors, based on some ‘very solid’ preclinical data they had generated.
As a result, their CAR-T approach has a distinct mechanism that doesn’t only kill the cells like most CAR-T – but also changes the tumor microenvironment (an interesting area in Immunotherapy – as discussed in our panel).
…it will differentiate us from other CAR-T companies.”
And how did Novartis change the CAR-T field, with results which are obviously very impressive.